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Previewsthat SR9243 metabolically reprograms
the rapidly growing cancer cells to
‘‘normal’’ metabolic cells that cannot
sustain cancer cell growth, and this trig-
gers apoptosis of the cancer cells. The
authors extend our molecular under-
standing of the transcriptional network of
LXRs by introducing an inverse agonist.
In the unliganded form, LXRs are associ-
ated with transcriptional corepressors.
Upon agonist activation, LXRs undergo
a conformational change where the
corepressors dissociate and transcrip-
tional coactivators are recruited. SR9243
interacts with LXRs and strengthens
the binding of LXRs to corepressors,
and thereby this inverse agonist sup-
presses LXR-mediated transcription of
target genes to below basal levels.
Furthermore, SR9243 sensitizes chemo-
therapy treatment using cytotoxic drugs
(50-fluorouracil and cisplatin) in a combi-
nation treatment strategy. Convincingly,
in vivo experiments using xenograft
models confirmed the anti-tumor effect
of SR9243 and reduced expression of
glycolytic lipogenic enzymes without
inducing weight loss.
Multiple studies report on the anti-in-
flammatory feature of LXRs (Jakobsson
et al., 2012), and studies have reported
that tumors produce LXR agonists to4 Cancer Cell 28, July 13, 2015 ª2015 Elseviavoid the body’s tumor immune surveil-
lance (Villablanca et al., 2010). Flaveny
et al. (2015) show that SR9243 specifically
induces expression of TNF-a in tumor
cells and suggest that SR9243 could
‘‘unmask’’ tumors to be recognized by
the immune system. Cytokines in the
tumor microenvironment are acknowl-
edged as important factors involved in
the control of tumor growth. Interestingly,
a recent study linked LXR-mediated
survival rates and tumor free animals
in lung cancer xenograft models to
increased interferon-g production (Wang
et al., 2014). While the anti-inflammatory
role of LXR is well documented, the cross
talk between the effect of LXR signaling
in metabolism and the LXR-mediated
modulation of the immune response
dealing with tumors has only recently
been investigated. While Flaveny et al.
(2015) provide interesting evidence that
targeting LXRs to suppress glycolysis
and lipogenesis is a promising new
strategy for cancer treatment, further
studies investigating the impact and
association of LXR signaling in meta-
bolism, immunity/inflammation, and pro-
liferationmight unravel novel mechanisms
to advance the battle against cancer.
And the inverse agonist SR9243 could
prove a valuable tool in this quest.er Inc.REFERENCES
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In this issue of Cancer Cell, Mohammad et al. describe LSD1, a histone demethylase, as a therapeutic target
in SCLC with a unique epigenetic signature to predict drug sensitivity. Inhibition of LSD1 reduces cell prolif-
eration and stem cell maintenance while promoting cell differentiation and reducing tumor growth in preclin-
ical models.Small cell lung carcinoma (SCLC) is one of
the most genetically complex cancers
(Peifer et al., 2012). Beyond mutations,
epigenetic changes also play a key role
in promoting aggressive behavior ofSCLC. 31,000 patients are diagnosed
with SCLC annually in the United States,
a majority of whom have widely dissemi-
nated disease at presentation and will
succumb to their cancer within a yeardespite current treatments. Unlike non-
small cell lung carcinoma (NSCLC), where
a growing number of druggable genetic
alterations have transformed treatment
(e.g., EGFR mutations and ALK, RET,
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Previewsand ROS1 fusions), in SCLC there are
currently no targeted therapies with es-
tablished efficacy and there are no vali-
dated biomarkers to guide treatment
selection. As a result, a decades-old
regimen of platinum-etoposide chemo-
therapy remains the standard of care.
A major challenge in treating SCLC is
the rapid emergence of drug resistance,
which typically occurs within months of
completing chemotherapy. Average sur-
vival after recurrence is only 4-6 months
due to a lackof effective second-line treat-
ment options. Previous studies in a variety
of cancer types have demonstrated the
ability of epigenetic therapy to modulate
the expression of genes regulating che-
moresistance and other critical oncogenic
behaviors (Azad et al., 2013).
Recently, by comparing methylation
patterns in SCLC tumors versus normal
lung, Poirier et al. (2015) demonstrated
that methylation regulates key SCLC
genes, including overexpression of BCL2
and silencing of RB1. Using human tu-
mors, patient-derived xenografts (PDXs),
and cell lines, they then identified distinct,
reproducible methylation subgroups
within SCLC that likely represent subsets
with distinct therapeutic responses.
Some of these epigenetic changes may
be regulated by recurring mutations that
include several chromatin modifiers and
epigenetic readers (Peifer et al., 2012;
Rudin et al., 2012).
Clinically, FDA-approved indications
for epigenetic therapies are limited to
hematological malignancies. However,
epigenetic machinery has emerged as
an important target for additional dis-
eases including lung cancer. In SCLC,
preclinical activity of the histone deacety-
lase inhibitors vorinostat and belinostat
in combination with cisplatin/etoposide
(standard first-line treatment) or topote-
can (the only FDA approved second-line
therapy for SCLC) has led to clinical trials
investigating these drugs in combination
with chemotherapy.
In this issue ofCancer Cell, Mohammad
et al. (2015) describe the discovery
and characterization of GSK2879552, a
selective, highly potent small molecule
inhibitor of lysine demethylase 1 (LSD1).
LSD1 is a histone modifier that maintains
the pleuripotency of embryonic stem cells
through demethylation of histone H3
lysine 4 (H3K4) and subsequent repres-
sion of genes controlling cell differentia-tion (Adamo et al., 2011). Prior studies
have shown that LSD1 is overexpressed
in many cancer types and that inhibition
promotes differentiation and reduces
cancer cell growth, migration, and inva-
sion (Lv et al., 2012).
Because of its central role in stem cell
maintenance and cancer progression, the
authors sought to identify potent inhibitors
of LDS1. This led ultimately to the identifi-
cation of three LSD1 inhibitory molecules,
including GSK2879552 and GSK-LSD1.
Further characterization demonstrated
that GSK2879552 completely and irre-
versibly inactivates LSD1’s enzymatic
activity and is highly specific for LSD1,
despite LSD1 having a structure closely
related to LSD2, MAO-A, and MAO-B.
The authors then treated 165 cell lines
representing multiple cancer types with
the newly discovered inhibitors. Most
were insensitive to GSK2879552; how-
ever, a significant subset of acute myeloid
leukemia (AML) and SCLC cell lines were
sensitive. The sensitivity of AML to LSD1
inhibition was not surprising based
on previously published reports (Harris
et al., 2012) and the established use of
epigenetic therapies for AML. In contrast,
activity in SCLC cell lines (30% of those
tested) was a novel and unexpected
observation—and one with the potential
to address a significant unmet need.
As such, the authors performed a
detailed investigation into the effects of
GSK2879552 in SCLC models.
Consistent with the pro-differentiation
effect of LSD1 inhibition, GSK2879552
was primarily cytostatic, rather than
cytotoxic, in SCLC preclinical models,
resulting in a delayed onset of growth
inhibition in vitro. Similarly, in SCLC xe-
nografts, tumors did not significantly
regress, but rather growth was pro-
nouncedly delayed in treated animals
versus controls.
Confident in the therapeutic activity of
GSK2879552 in SCLC models, the inves-
tigators then demonstrated that LSD1
protein is highly expressed in patient
tumors and that expression of genes
involved in neuroendocrine differentiation
(a hallmark of SCLC) changed following
GSK2879552 treatment. Next, an inte-
grated analysis of epigenetic changes
caused by LSD1 inhibition found LSD1
and H3K4 methylation enrichment sur-
rounding transcriptional start sites of
genes involved in the regulation of cellCancer Cstate. These findings implicate a role for
LSD1 in maintaining SCLC stemness,
with LSD1 inhibition promoting differenti-
ation, similar to what has been observed
in other cancer types.
Because only a subset of SCLCmodels
demonstrate sensitivity to LSD1 inhibi-
tion, the authors were interested in bio-
markers that could potentially identify
those SCLC patients likely to derive the
greatest benefit from LSD1 targeted
therapy. They failed to identify mRNA
biomarkers but did identify a set of 45
methylation probes with differences be-
tween sensitive and resistant preclinical
models. Critically, these 45 probes also
separated SCLC human tumors and/or
PDX models into two groups—supporting
their potential to stratify patients based on
the likelihood of response. Most intrigu-
ingly, the authors then demonstrated the
ability of their methylation signature
‘‘score’’ to correctly predict the response
of three PDX models to treatment with
GSK2879552 (Figure 1A).
Taken together, the findings in this
study support GSK2879552 as an LSD1
inhibitor with potential activity against
SCLC. Today, patients with SCLC
continue to be treated with a ‘‘one-size-
fits-all’’ approach using chemotherapy
regimens that have not significantly
changed in 30 years. However, a growing
understanding of the molecular heteroge-
neity of this disease should allow us to
exploit unique molecular features of an
individual’s cancer to target specific
therapeutic vulnerabilities. The preclinical
findings described in this issue are of
particular translational relevance given
a current multicenter phase 1 study of
GSK2879552 in patients with relapsed/
refractory SCLC (NCT02034123).
Given the critical issue of drug resis-
tance in SCLC and the potential contribu-
tion of stem-cell enrichment to this clinical
problem, the introduction of a novel
drug that promotes differentiation may
be especially effective in treating or pre-
venting SCLC relapse. SCLC cell lines
contain large populations of stem cells
(Sullivan et al., 2010), which are impli-
cated in chemotherapy resistance and
metastasis, both of which are major chal-
lenges in SCLC. In fact, CD133 levels, a
marker of stem cells, were elevated in
SCLC tumors following chemotherapy
(Sarvi et al., 2014). By promoting differen-
tiation, rather than stem cell maintenance,ell 28, July 13, 2015 ª2015 Elsevier Inc. 5
Figure 1. Proposed DNA Hypomethylation Signature to Predict SCLC Sensitivity
(A) A signature of 45 differentially methylated CpGs was associated with in vitro sensitivity to the LSD1 in-
hibitor GSK2879552. To test the performance of the methylation signature, patient-derived xenografts
(PDXs) were scored to predict drug response. Two PDXs with positive methylation signature scores re-
sponded to GSK2879552, whereas a PDX with a negative score was resistant.
(B) Clinical schema of proposed mechanism of GSK2879552 in a biomarker selected SCLC patient pop-
ulation. Following an initial treatment period with chemotherapy, treatment of stem-cell enriched residual
SCLC tumor leads to further regression and disease control.
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PreviewsLSD1 inhibition may prolong sensitivity to
chemotherapy.
The work presented here represents
an exciting step toward the possibility
of personalized cancer therapy in
SCLC. Nevertheless, important questions
remain. First, further investigation into the
mechanism of action of GSK2879552 in
SCLC is warranted given that methylation
markers—but not mRNA levels (which
should change in response to alterations
in methylation)—were predictive of drug
response. This raises the possibility of
additional mechanisms by which the6 Cancer Cell 28, July 13, 2015 ª2015 ElseviLSD1 inhibitor may be acting, such as
decreasing the stability of E2F1 protein
(Kontaki and Talianidis, 2010). SCLC is
an E2F1 ‘‘addicted’’ tumor due to the
loss of RB1, and this may contribute to
its sensitivity to LSD1 inhibition. Second,
the ongoing clinical trial will begin to
address whether GSK2879552 has single
agent activity in patients with relapse.
However, this drug may be most effective
in the maintenance setting after the bulky
disease has been reduced by chemo-
therapy and a cancer stem cell population
may be enriched and poised for diseaseer Inc.recurrence (Figure 1B). In conclusion,
this is a promising novel therapeutic agent
with unexpected activity in SCLC. In
addition to introducing potentially active
epigenetic therapy, this study provides
the first epigenetic biomarker for SCLC
and represents a step toward more
tailored treatment for SCLC patients.ACKNOWLEDGMENTS
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